Early phase trials play a crucial role in drug development, determining the dose to test in later phases. With the rise of combination treatments, there is a growing need for innovative and efficient trial designs to navigate this complex landscape. Discover how new research is paving the way for more efficient and flexible strategies in early phase combination trials, increasing our chances of identifying safe and efficacious dose levels.
Speakers:
- Dr Pavel Mozgunov, Program Leader Track, MRC Biostatistics Unit, University of Cambridge
- Weishi Chen, PhD Student, MRC Biostatistics Unit, University of Cambridge
- Matt George, Senior Statistician, Phastar
- Sam Hinsley Moderator, Statistics Manager, Phastar
Learning Points:
- Summarize the key considerations in early phase combination trials.
- Explore a range of trial designs that can enhance efficiency in the combination setting.
- Present new research on a novel method for inserting dose levels mid-trial, offering a fresh approach to improve trial adaptability.
This session is designed to increase awareness of both established and innovative solutions that can improve outcomes in early phase combination trials.
Complete the form below to access the recording and slides.
